Enzyme Replacement Therapy for Gaucher Disease (Cerezyme, Elelyso, Vpriv) C9674-A
Use of Identical INN “Imiglucerase” for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database | Drug Safety
Cerezyme® (imiglucerase)
A Guide to Cerezyme (imiglucerase for injection) Billing and Reimbursement
SPECIALTY QUANTITY LIMIT PROGRAM
M:\NDAs\NDA 20-367 Cerezyme\S-053 SLR\AP-LTR
Cerezyme® (imiglucerase)
Imiglucerase - wikidoc
Cerezyme® (imiglucerase)
Last Review Status/Date:
Public Summary
Cerezyme® (imiglucerase)
3 Cerezyme Home Infusion Patients ManualV2 14-1
POLICY Document for Cerezyme
PHARMACY POLICY STATEMENT
1 Louisiana Medicaid Enzyme Replacement Therapy The Louisiana Uniform Prescription Drug Prior Authorization Form should be uti
Use of Identical INN “Imiglucerase” for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database | Drug Safety
Last Review Status/Date:
Policy Title: Cerezyme (imiglucerase), Elelyso (taliglucerase alfa), VPRIV (velaglucerase alfa) Intravenous Department: PHA Ef
Cerezyme® (imiglucerase for injection) Preparation & Administration Brochure
Cerezyme® (imiglucerase)
Imiglucerase - wikidoc
Use of Identical INN “Imiglucerase” for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database | Drug Safety
IMIGLUCERASE POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
Enzyme Replacement Therapy (IV) for Gaucher Disease C9674-A_R
Cerezyme® (imiglucerase) Home Infusion:
Protocol RC 92-0501: An Extended Evaluation of the Safety and Effectiveness of Recombinant, Human- derived, Macrophage-Targeted
